Last reviewed · How we verify
Nerve Growth Factors
Nerve Growth Factor (NGF) promotes the survival, growth, and differentiation of nerve cells, enhancing neuronal repair and regeneration.
Nerve Growth Factor (NGF) promotes the survival, growth, and differentiation of nerve cells, enhancing neuronal repair and regeneration. Used for Peripheral neuropathy, Nerve injury and regeneration, Diabetic peripheral neuropathy.
At a glance
| Generic name | Nerve Growth Factors |
|---|---|
| Sponsor | Jinling Hospital, China |
| Drug class | Neurotrophic factor |
| Target | TrkA receptor, p75 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
NGF is a neurotrophic protein that binds to TrkA and p75 receptors on neurons, activating signaling pathways that support neuronal survival and axonal growth. It is used clinically to promote peripheral nerve regeneration and functional recovery in peripheral neuropathies and nerve injury conditions. The mechanism involves stimulation of endogenous repair processes and reduction of neuronal apoptosis.
Approved indications
- Peripheral neuropathy
- Nerve injury and regeneration
- Diabetic peripheral neuropathy
Common side effects
- Injection site reactions
- Pain at injection site
- Local inflammation
Key clinical trials
- A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer (PHASE2)
- The Biopsychosocial Model to Identify Risk Factors for Chronic Post-traumatic Pain in ICU Patients
- AAV2-GDNF for Advanced Parkinson s Disease (PHASE1)
- Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG) (PHASE2)
- Platelet Rich Plasma Injections In Young And Old Human Subjects (PHASE2)
- The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy (PHASE2, PHASE3)
- Kinetics of Plasma and Serum Levels of Brain-Derived Neurotrophic Factor (BDNF) in Patients With Ischemic Stroke (NA)
- A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With HR+, HER2- Advanced Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nerve Growth Factors CI brief — competitive landscape report
- Nerve Growth Factors updates RSS · CI watch RSS
- Jinling Hospital, China portfolio CI